lapatinib has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Trials (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Recent Studies (post-2010) (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,473 | 3 | 1,057 |
| Protein | Taxonomy | lapatinib (IC50) | benzyloxycarbonylleucyl-leucyl-leucine aldehyde (IC50) |
|---|---|---|---|
| Proteasome subunit beta type-11 | Homo sapiens (human) | 1.9893 | |
| Calpain-9 | Homo sapiens (human) | 9.88 | |
| Proteasome subunit alpha type-7 | Homo sapiens (human) | 1.9893 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 3.9 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.8999 | |
| Aromatase | Homo sapiens (human) | 0.044 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 0.5 | |
| Proteasome subunit beta type-1 | Homo sapiens (human) | 1.0853 | |
| Proteasome subunit alpha type-1 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-2 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-3 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-4 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-8 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-9 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha type-5 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-4 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-6 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-5 | Homo sapiens (human) | 0.6088 | |
| Proteasome subunit beta type-10 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-3 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-2 | Homo sapiens (human) | 2.0443 | |
| Proteasome subunit alpha type-6 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit alpha-type 8 | Homo sapiens (human) | 1.9893 | |
| Proteasome subunit beta type-7 | Homo sapiens (human) | 1.9893 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrasco-Pancorbo, A; Fernandez-Gutierrez, A; Garcia-Villalba, R; Menendez, JA; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A | 1 |
1 other study(ies) available for lapatinib and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Topics: Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flavonoids; Humans; Lapatinib; Leupeptins; Lignans; Olive Oil; Phenols; Phosphorylation; Plant Oils; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Trastuzumab | 2008 |